Navigation Links
ORTHO Sera ID-MTS Antigen Phenotyping Cleared on ORTHO VISION® Platforms in United States and Canada
Date:3/10/2020

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format used for blood phenotyping for patients in need of transfusion, is cleared to run on ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The clearances allow testing for more than 99 percent of the most commonly tested blood group antigens to be performed on one platform, driving greater value and efficiency.

The suite was cleared by the U.S. Food and Drug Administration for use on the ORTHO VISION® Analyzer in October 2019, and for use on the ORTHO VISION® Max in January 2020. The suite received Health Canada approval in January 2020.

Watch a video on how Sera works: https://www.youtube.com/watch?v=wL2oVvFXhsY.

“Ortho Clinical Diagnostics is proud to offer our laboratory partners solutions that help them quickly test donor blood for the most-needed phenotypes and confidently provide it to patients in need of transfusion,” said Bob Stowers, head of Ortho's transfusion medicine product portfolio. “With the ability to analyze the most commonly tested antigens on a single ORTHO VISION system and results in under 25 minutes, lab teams are better equipped to help clinicians focus on what matters most—treating their patients.”

During pre-transfusion testing, lab professionals routinely encounter complex patient samples that require extended antigen typing. These patients have developed atypical antibodies to blood group antigens and require additional testing to find compatible blood.

Its antisera additive approach means customers always have the appropriate reagents available and allows extended phenotyping to be personalized according to patient needs—reducing waste and enhancing efficiency.

With end-to-end full automation on the ORTHO VISION and ORTHO VISION Max analyzers, ORTHO Sera minimizes the potential for human error—improving safety—and provides consistent, reliable results while freeing up lab professionals to focus on value-added tasks.

The 13 ORTHO Sera reagents available in the U.S. and Canada on the ORTHO VISION Analyzer and ORTHO VISION Max include Anti-D (DVI), Anti-D (IAT), Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-K, Anti-Lea, Anti-Leb, Anti-N, Anti-P1, Anti-S, Anti-s.

For more information, visit https://www.orthoclinicaldiagnostics.com/en-us/home/ortho-sera.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, serves the clinical laboratory and immunohematology communities.

Ortho’s high-quality products and services help hospitals, hospital networks, blood banks and labs in more than 125 countries and territories deliver consistently fast, accurate, and reliable results that allow clinicians to make better-informed treatment decisions.

Ortho’s lab solutions provide sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories to help them run more efficiently and effectively and improve patient care.

Ortho’s blood typing products help ensure every patient receives blood that is safe, the right type and the right unit.

Why does Ortho continue to innovate and provide industry-changing solutions? Because every test is a life.

For more information about Ortho’s solutions and services, visit http://www.orthoclinicaldiagnostics.com, or visit Ortho on social media: LinkedIn, Twitter, Facebook, Instagram and YouTube.

Read the full story at https://www.prweb.com/releases/ortho_sera_id_mts_antigen_phenotyping_cleared_on_ortho_vision_platforms_in_united_states_and_canada/prweb16967214.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. VGI Medical Engages Ortho Spine Partners (OSP) to Lead US Commercialization Efforts
2. Independent Orthodontic Practices to Gain Access to Advanced Data Solutions
3. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, will present a clinical abstract on Allogeneic Adipose Stem Cell Bio-Distribution at the Veterinary Orthopedic
4. Ortho Clinical Diagnostics Recognized with Two Global Business Excellence Awards
5. Brian Mehling, M.D., US orthopedic trauma surgeon, stem cell researcher, founder of Blue Horizon International to attend World Economic Forum in Davos
6. New Orthopedic Device Technology Moves From Lab Toward Operating Room With Help From Philadelphia-Based Start-Up OrthoMend Research, Inc.
7. Orthogonal Congratulates Nanowear on the FDA Clearance of their Flagship Product, SimplECG™.
8. Orthopedic Surgeon Speaks On Using Medicrea’s Patient-Specific UNiD Rods To Treat Scoliosis
9. Global Orthobiologics Market Outlook 2020 - Research and Markets
10. Smarter Alloys Announces Commercial Launch of SmartArch Orthodontic Archwire
11. In’Tech Medical Expands in Asia with the Acquisition of Ortho Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. has ... be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI Radar ... switches in a push-pull configuration; yielding fast fall time for a capacitive load. ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... the life sciences industry, today announced the release of its signature product ... Medical Science Liaisons (MSLs) and other field medical professionals. , Beacon ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , a leading ... food industries, is pleased to announce that Charles Galea has joined its clinical ... Charles is an accomplished and results-driven sales executive with over 10 years of ...
(Date:7/7/2020)... ... July 06, 2020 , ... R3 International is now ... up to 200 million stem cells. Depending on the patient's condition, treatment may be ... US will die having some form of Alzheimers dementia, and the incidence continues to ...
Breaking Biology Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from the Centers ... making them the first Wharton’s jelly allografts to be assigned a Q code and ... are the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P ...
(Date:7/18/2020)... SAN ANTONIO (PRWEB) , ... July 16, 2020 ... ... PLOS ONE that demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise ... (NICU) environment. The study reported that the Neoasis™ device attenuated the alarm sounds ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), ... Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, ...
Breaking Biology News(10 mins):